Research Focus
My research studies the role of growth and survival signaling pathways in colorectal cancer, focusing on the effects of selective therapeutics against nodes in these pathways. I am interested in the dysregulation of mitogen-activated protein kinase (MAPK) signaling that commonly occurs in colorectal cancer, resulting from epidermal growth factor receptor (EGFR) activation or activating mutations in RAS or RAF, and the consequences of this dysregulation on parallel and downstream signaling. A representative work is a Nature paper describing the emergence of KRAS mutations with acquired resistance to EGFR targeting agents. As an assistant attending physician I am interested in using this understanding to guide the selection of patient populations whose tumors are likely to respond to MAPK or PI3K (phosphatidylinositol 3-kinase) pathway inhibitors, and to suggest rational therapeutic combinations to enhance the antitumor effect of these agents.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Rona Yaeger discloses the following relationships and financial interests:
-
Mirati Therapeutics
Professional Services and Activities
-
Zai Lab
Professional Services and Activities
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures